Table 1.
Diagnostic sensitivity and specificity evaluation results of BLF Rapid using stored serum samples at each laboratory
| Institution | Reactivity with different types of sera | Sensitivity (%) | Specificity (%) | |||
|---|---|---|---|---|---|---|
| Wb | Tests used to determine Wb infection | Other infections | Healthy | |||
| USM | 55/55 | mf | 0/31* | 0/10 | 100 | 100 |
| UM | 3/3 | mf and ICT | 0/2† | 0/1 | 100 | 100 |
| IMR | 7/7 | ICT | – | – | 100 | – |
| NIH-NIRT-ICER | 28/28 | ICT and Og4C3-ELISA | – | 0/50 | 100 | 100 |
| CDC | 32/38 | mf and/or ICT and/or Bm14-ELISA | – | 0/10 | 84 | 100 |
| WUSTL | 23/23 | mf and AD12-ELISA | – | – | 100 | – |
| Average‡ | 93/99 (94%) | – | – | – | – | 100 |
CDC = Centers for Disease Control and Prevention, Atlanta, GA; ICT = Filariasis card test; IMR = Institute for Medical Research, Malaysia; mf = microfilaria; NIH-NIRT-ICER = National Institutes of Health-International Center for Excellence in Research, National Institute of Research in Tuberculosis, India; UM = University of Malaya, Malaysia; USM = Universiti Sains Malaysia; Wb = Wuchereria bancrofti infection; WUSTL = Washington University School of Medicine, USA.
* Serum samples were from patients living in non-LF endemic areas with ascariasis, trichuriasis, hookworm infection, strongyloidiasis, toxocariasis, hydatid disease, amoebic liver abscess, and toxoplasmosis.
† Serum samples were from patients living in non-LF endemic areas with toxoplasmosis and amoebiasis.
‡ Average sensitivity and specificity were calculated from percentage values across all laboratories excluding USM.